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Abstract
Xerostomia or dry mouth sensation is considered a complex condition that affects several 
stomatological functions that drives to the detriment of the quality of life of individuals 
who suffer from it. Often, xerostomia is accompanied by a decrease in salivary flow or 
hyposalivation, and this condition leads to oral health problems such as dental caries, can-
didiasis, and mucosal complications. Currently, the diagnosis and therapeutic methods 
for this condition are varied and it is difficult to achieve favorable results in all cases, since 
the etiology seems to be multifactorial where both local factors and systemic conditions 
would participate. This chapter presents, in a concise shape, the relevant data about etiol-
ogy of xerostomia, such as age, autoimmune diseases, systemic diseases, infectious dis-
eases, neuropathic complications, psychogenic factors and therapeutically consumption of  
drugs among others, and the current available treatments.
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1. Introduction
Xerostomia or dry mouth sensation is considered a complex condition that affects several 
stomatological functions and drives to the detriment of the quality of life of individuals who 
suffer from it. Often, xerostomia is accompanied by a decrease in salivary flow or hyposal-
ivation with consequences such as oral lesions, alterations of taste, feeling of thick saliva, 
chewing problems, dental caries, dental demineralization, periodontal disease, salivary gland 
infection, cervical caries, fungal infections, and others [1]. Currently, the diagnosis and thera-
peutic methods for this condition are varied and it is difficult to achieve favorable results in 
all cases, since the etiology seems to be multifactorial where both local and systemic factors 
would participate [2–5]. Although xerostomia may occur frequently in the general popula-
tion, clear and defined tools for diagnosis and treatment are still needed. Today, patients suf-
fering from xerostomia visit numerous health professionals to solve this complex condition 
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that limits many functions of day-to-day life, and often does not find response or effective 
treatment. Regards the complexity of xerostomia and its importance in dental practice, this 
chapter reviews the relevant data about etiology, diagnosis, consequences, and the current 
available treatments to this condition.
2. Definition and evaluation
Xerostomia (dry mouth, oral dryness, and mouth dryness) is the dryness of oral cavity and 
can be caused by lower salivary flow or the complete lack of saliva [6]. Based on the etiology, 
the xerostomia can be classified as true xerostomia (xerostomia vera, primaria), caused by the 
malfunction of the salivary glands and pseudo xerostomia or symptomatic xerostomia (xero-
stomia spuria, symptomatica), which is described as the subjective sensation of oral dryness, 
despite normal secretory function of the salivary glands [7]. The xerostomia, as a symptom, is 
more common in older populations, but its causes are not related to aging. It has been shown 
it is related to some specific diseases, drugs, or therapies associated [8]. The prevalence of 
xerostomia varies from 13 to 28% in older populations, and increases up to 60% in patients 
living in long-term care facilities [9–11].
Xerostomia, although not considered a disease, may imply the presence of changes directly 
related to the salivary glands or be the result of systemic diseases [12]. In order for a suitable 
treatment to be instituted in a timely manner, it is important to carry out a thorough evalu-
ation of the patient with the dry mouth condition, determining, if possible, the cause of the 
xerostomia. The patients with xerostomia, who are present with salivary gland hypofunction, 
are at risk of many oral complications; the persistence over time of low rates of salivary secre-
tion causes changes in the oral environment and affects the hard and soft tissues of the mouth. 
Xerostomia can also be a consequence of systemic disease and its recognition is a valuable aid 
in the treatment [13]. It is a potentially debilitating condition that can affect up to 1 in 5 oncol-
ogy patients, with higher prevalence in women and the elderly. There is evidence that the use 
of multiple medications may increase the risk of xerostomia [13]. This symptom represents a 
strong impact on the quality of life of the people affected. Over 87.6% of people with xerosto-
mia were worried if they had to spend the rest of their lives with the dry mouth sensation [14]. 
The dry mouth (xerostomia) sensation has a higher incidence on individuals over 60 years 
old (12–40%), up to three times higher than on younger adults. It does not seem to be directly 
related to the normal aging process, but to some chronic diseases or treatments [15, 16]. It is 
estimated that about 20–30% of the 20-year-old population has xerostomia and the cause may 
be the increased use of antidepressants, since xerostomia is associated with depression and 
anxiety. In United States, up to 40% of the 20-year-old population may have xerostomia. The 
high consumption of antidepressants and other medications, as well as alcoholic beverages 
and tobacco may explain the increase in people with this condition [17].
Although xerostomia, as a symptom, entails many problems for patients who suffer from it, 
especially in relation to their quality of life, the decrease in the amount of saliva due to its mul-
tiple properties is what brings more consequences at the oral level. Saliva is composed of 99% 
water and electrolytes. The rest of the composition is organic and includes immunoglobulins, 
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digestive enzymes such as amylase and lipase, and antibacterial and antifungal enzymes, as 
well as mucins [14]. Ninety-three percent of its volume is secreted by the major salivary glands 
and the remaining 7% by the minor glands. Saliva production is controlled by the autonomous 
nervous system, mainly by parasympathetic nerve signals [18]. Saliva is very important for 
the preservation of general and oral homeostasis. It has a participation in digestives functions, 
cleaning, sense of taste, oral mucosa hydration, and defense of teeth trough pH control and its 
remineralizing potential. In addition, it has antimicrobial properties and controls the composi-
tion of oral microbiota by its antibacterial, antiviral, and antifungal capacities [14]. A summary 
of the Saliva components and functions can be seen in Table 1.
Several short and long-term conditions can interrupt salivary secretion, leading to xerosto-
mia. Xerostomia can thus result from three basic causes:
(1) Factors affecting the salivary center: psychological problems (stress and anxiety), Par-
kinson’s disease, Alzheimer’s disease (changes in the ability to perceive oral sensations), 
menopause, and others;
(2) Factors that alter nerve stimulation of saliva: encephalitis, brain tumors, smoking and de-
hydration (resulting from the deficiency of water intake, vomiting, diarrhea and polyu-
ria), as well as the use of some drugs, including antihistamines, opioids, antidepressants, 
antiepileptics, anxiolytics, anticholinergics, antimuscarinics, and others;
(3) Alterations in salivary gland function as a consequence of obstruction, infection (sial-
odenitis), glandular tumors, calculi (sialolithiasis), autoimmune diseases (Sjögren’s 
syndrome-SS-, rheumatoid arthritis, uncontrolled diabetes mellitus and systemic lupus 
erythematosus), and chemotherapy or radiotherapy performed as cancer therapy for the 
head and neck area. The extent of injury induced by radiotherapy depends on the volume 
of irradiated glands and the total dose and technique used [15, 19–23].
Functions Components
Digestion Amylase, lipase, ribonucleases, proteases, water, mucins
Phonation Water, mucin
Taste Water, gustin
Lubrication Mucin, proline-rich glycoproteins, water
Antimicrobial action Lysozyme, lactoferrin, lactoperoxides, mucins, cystins, histatins, 
immunoglobulins, proline-rich glycoproteins, IgA
Maintaining mucosa integrity Mucins, electrolytes, water
Cleansing Water
Buffer capacity and remineralization Bicarbonate, phosphate, calcium, staterin, proline-rich anionic proteins, 
fluoride
Preparing food for swallowing Water, mucins Digestion Amylase, lipase, ribonucleases, proteases, 
water, mucins
Table 1. Saliva components and functions.
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3. Diagnosis of xerostomia
The objective of the diagnosis is to provide treatment as early as possible, thus minimizing 
side effects in patients suffering from xerostomia. In order to establish a diagnosis of xerosto-
mia, a clinical history is essential to identify the possible etiological factors [24]. It is necessary 
to investigate its causes. Thus, three orders of factors need to be known: the occurrence of 
systemic diseases, medication, and the history of radiation therapy. Questions are asked to 
the patient, trying to find out if he feels the dry mouth sensation, whether he needs to wet his 
mouth, if he can eat a wafer without drinking water, if the tongue chews the food and clings to 
the teeth, and the daily water intake daily among other issues [24, 25]. The qualitative clinical 
diagnosis of xerostomia is made through the observation of clinical signs such as palpation 
of the salivary glands, observation of the oral mucosa and its hydration, cracked lips, saliva 
under the tongue, appearance and texture of saliva, the identification of caries, candidiasis 
and burning sensation, and others [26].
Several methods have been developed to evaluate the level of dryness of the mouth, the 
discomfort being the most used: sialography, sialochemistry, sialometry and scintigraphy, 
salivary gland biopsy, ultrasound, magnetic resonance, and computed tomography [19]. 
Sialography is a technique of imaging that involves the injection of a retrograde form of radi-
opaque material into the salivary duct system in order to define the anatomy of the glands. 
This test is very important to demonstrate the presence of nodules or sialectasis, but it has 
its disadvantages, such as: the difficulty of the technique, since it is invasive and the patient 
can react acutely or chronically with the contrast material. The biopsy of the major or minor 
salivary glands allows the detection of inflammatory infiltrations, acinar destruction and dila-
tion of salivary channels with thick mucus, and sometimes fibrosis [27]. Ultrasound, magnetic 
resonance, and computed tomography are tests that may also contribute to the diagnosis of 
diseases of the salivary glands.
To establish the condition of the symptom or to evaluate a possible salivary glandular dys-
function, the most used mechanisms are the questionnaire of xerostomia developed by Fox 
et al. [11, 28] and the determination of salivary flow rate. Sialometry and scintigraphy (an 
imaging diagnostic method of nuclear medicine that allows the study of the physiology of 
the various organs) are complementary tests that must be performed in order to evaluate 
the involvement of the salivary glands in patients with xerostomia. Sialometry is a relatively 
common procedure in normal clinical practice and include determination of stimulated sali-
vary flow rate (s-SFR), unstimulated salivary flow rate (u-SFR), palatal secretion (PAL), and 
parotid secretion (PAR). These measurements are the simplest methods of evaluating the 
salivary glandular function. It is essential to measure the salivary flow, that is, the amount 
of saliva produced per unit of time. Very low unstimulated and stimulated salivary flow 
rates or hyposalivation are defined as <0.1 and <0.7 mL/min, respectively [7]. At rest, secre-
tion ranges from 0.25 to 0.35 mL/min and is mostly produced by the submandibular and 
sublingual glands [29]. Under stimulation, the parotids account for 50% of salivary volume 
[30]. Determining the stimulated and unstimulated salivary flow is a procedure to measure 
the amount of saliva it produces a person at a given time. Generally, the stimulated salivary 
flow is measured for 5 min and unstimulated salivary flow is measured for 15 min [31]. This 
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kind of measuring has the advantage of being easily implemented, low-cost, and could be 
available to most of the population at risk [32]. The diagnosis of salivary gland dysfunction 
is based on data derived from the symptoms reported by the patient, clinical examination 
leading to verification of the clinical signs and determination of stimulated salivary flow [33]. 
A severe decrease in salivary flow may lead to a poor health-related quality of life, as well as 
a risk condition for the development of oral pathologies such as periodontal disease, caries, 
and candidiasis [29, 34, 35].
4. Causes of xerostomia
The most severe conditions with effect on the salivary flow are SS and radiotherapy in the 
head and neck area, with the prevalence of xerostomia in almost 100% in these cases. These 
conditions are characterized by a progressive loss of secretory cells, and thus a progressive 
decline in saliva production [36, 37]. Less severe conditions may be dehydration, smoking, 
and inflammation or infection of the salivary glands [12]. In older people, the most common 
cause of xerostomia is the use of medications because the vast majority of the elderly are being 
treated with at least one drug that causes salivary hypofunction [32]. A summary of the main 
causes of xerostomia can be seen in Table 2.
4.1. Aging
The reduced salivary flow is commonly seen in the aging populations. This can be attributed 
to either age-related localized degeneration of salivary glands or systemic diseases [38, 39]. 
As the patient ages, the organs atrophy and often result in a decrease in salivary production. 
It was described that in older people the loss was about 30% of acinar cells, with substitu-
tion of secretory components by fibrous and adipose tissue [40]. Besides, there are changes 
in salivary levels of potassium, sodium, IgA, proline-rich protein, lactoferrin, and lysozyme 
in elderly [28, 40]. A reduction in salivary flow of older people was identified, even in those 
not using systemic drugs, suggesting a relation between salivary dysfunction and aging [41]. 
Smith determined that a stimulated salivary flow in healthy adults older than age 70 is lower 
than in adults under 50 [42].
Systemic diseases Sjogren’s syndrome, diabetes mellitus, Parkinson’s disease, encephalitis, brain tumors, 
Plummer Vinson disease, hypertension, HIV infection, systemic rheumatic diseases, 
sarcoidosis, Alzheimer’s disease, cystic fibrosis, aplasia, chronic tuberculosis, primary 
biliary cirrhosis, hemolytic anemia, malignant lymphoma, systemic lupus erythematosus, 
scleroderma, dermatomyositis, pernicious anemia, hypothyroidism, amyloidosis
Other causes of 
xerostomia (no drugs or 
systemic diseases)
Radiotherapy and chemotherapy, infections, inflammation, tumors and sialolithiasis in 
salivary glands, salivary gland excision, vitamin A deficiency, menopause, stress, anxiety, 
dehydration, neurological disorders, senility, oral sensory dysfunction, iron deficiency, 
folic acid deficiency, uremia, polyuria, diarrhea, mouth breathing, bone marrow 
transplantation, endocrine disorders, pancreatic insufficiency
Table 2. Systemic diseases and other causes of xerostomia.
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4.2. Drugs
The most common cause of xerostomia is the use of some systemic medications [43]. Several 
drugs are able to induce hyposalivation and xerostomia, but they rarely cause irreversible 
damage to the salivary glands. Over 400 medicines, many of them in common use, induce 
salivary gland hypofunction [44]. Some examples are: anxiolytics, anticonvulsants, antide-
pressants, antiemetics, antihistamines, antiparkinsonian, antipsychotics, bronchodilators, 
decongestants, diuretics, muscle relaxants, analgesics, sedatives and anti-hypertensives, and 
others (Table 3) [29]. The exact mechanisms whereby some drugs determine xerostomia or 
hyposalivation are still unknown. Salivary dysfunction associated to drugs may occur through 
anticholinergic, cytotoxic action, sympathomimetic, or by damaged ion transport pathways in 
the acinar cells [39, 45, 46]. Patients who consume a higher number of daily medications have 
been associated with complaints of xerostomia [47, 48]. The therapeutic and controlled doses 
of medications do not damage the salivary gland structure. For that reason, drug-induced 
xerostomia is reversible. The discontinued use of these drugs can restore salivary flow [49].
4.3. Systemic conditions
Xerostomia or hyposalivation may be caused by local factors, including salivary gland disease 
(sialadenitis) or salivary gland destruction associated with head and neck irradiation for the 
Medicine group Examples
Anxiolytics Lorazepam, diazepam
Anorectic Fenfluramine
Anticonvulsants Gabapentin
Antidepressants—tricyclic Amitriptyline, imipramine
Antidepressants—SSRI Sertraline, fluoxetine
Antiemetics Meclizine
Antihistaminics Loratadine
Antiparkinsonian Biperidene, selegiline
Antipsychotics Clozapine, chlorpromazine
Bronchodilators Ipratropium, albuterol
Decongestants Pseudoephedrine
Diuretics Spironolactone, furosemide
Muscle relaxants Baclofen
Narcotic analgesics Meperidine, morphine
Sedatives Flurazepam
Antihyperptensive Prazosin hydrochloride
Antiarthritic Piroxicam
Table 3. Medicines and drugs with side effects on salivary secretion.
Salivary Glands - New Approaches in Diagnostics and Treatment20
treatment of cancer [11, 50]. The effects of radiation are dose, time, and field dependent. When 
the damage of salivary glands by radiation happens is severe [39] permanent gland damage 
can be expected if the radiation exposure exceeds 50 Gy [50, 51]. Other systemic conditions that 
also affect the salivary flow are autoimmune diseases (SS, rheumatoid arthritis, AIDS, systemic 
lupus erythematosis, and scleroderma), neurological disorders (Parkinson’s), psychogenic ill-
ness such as depression and hormonal disorders (thyroid dysfunction and diabetes mellitus) 
[9]. Regarding diabetes, we will refer more deeply about it since it is the most frequent meta-
bolic disease in the world and the trend demonstrates that it continues to grow. Both diabetes 
mellitus (DM) type 1, as type 2 have been associated with xerostomia. In diabetic subjects 
were shown that salivary flow was significantly lower than in nondiabetic subjects [49]. The 
causes of low salivary flow may be due to direct injury in the gland parenchyma, changes in 
the microcirculation to the salivary glands, glycemic control disorders, and dehydration. Some 
studies consider that this decrease in salivary flow in diabetic subjects is related to an increased 
diuresis or polyuria, involving a decrease in extracellular fluid and consequently in saliva pro-
duction [10]. Others explain this as a consequence of dehydration from glycosuria that would 
be more evident in cases of metabolic decompensation [52]. Regarding neurological diseases, 
studies have demonstrated that the salivary flow is lower in Parkinson’s disease patients. This 
phenomenon could contribute to dysphagia, which affects up to 75% of patients with this dis-
ease [53]. Autonomic dysfunction could explain the decrease in salivary flow in subjects with 
this disease and the drugs used to their treatment could increase the problem [54]. One of the 
diseases most associated with a xerostomia is SS, a condition that involves dry mouth and 
dry eyes and that may be accompanied by rheumatoid arthritis or a related connective tissue 
disease. The oral manifestations observed in this disease are attributed to the involvement 
of the salivary glands, which leads to a decrease in salivary secretion [31, 39]. Patients with 
depression can have hyposalivation medication-induced. However, xerostomia may be of psy-
chological origin. A study observed that subjects with a subjective sensation of dry mouth were 
significantly more depressive than non-depressive subjects [55]. Another study indicates the 
possibility of depression as an underlying factor of the sensation of dry mouth [56].
5. Consequences of xerostomia
Patients with xerostomia may have oral and dental consequences. Xerostomia can seriously 
impact quality of life and may alter speech, eating, and swallowing [13]. The most common 
complaints of patients with xerostomia include oral discomfort, difficulty speaking, dysphagia, 
dysgeusia (decreased taste), feeling of thick saliva, and generally, chewing issues, dental caries, 
dental demineralization, periodontal disease, salivary gland infection (sialodenitis), oral micro-
flora alterations, burning sensation, mucosal inflammation, sore throats, hoarseness, ulcerations, 
halitosis, mucosal dehydration, reduced lubrication, painful tongue (glossodynia), enlarged 
parotid gland, oral mucosal fracture, inflammation and fissures of the lips (cheilitis). The reduc-
tion of rates of elimination of substances can affect the palate and be associated with changes 
in the mouth microbiota. The reduction of rates of elimination of substances can affect the pal-
ate and be associated with changes in the mouth microbiota. From the mouth, alterations of 
taste and intolerance to acidic or spicy foods, dry foodstuffs like biscuits can be very uncomfort-
able for them, and oral cavity examination may exhibit signs such as fissures on the tongue and 
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lips, angular cheilitis, and dry mucosa. Also, caries, candidiasis, halitosis, or loss of appetite and 
weight could be observed [25, 57, 58]. This collection of clinical parameters has been indicated as 
simply estimated for recognizing most patients with xerostomia [38, 47].
The side effects associated with xerostomia are microbial colonization and proliferation in 
the oral cavity, dental or decreased demineralization, accumulation of stones in the teeth, 
dehydration of the mucosa, reduction of rates of elimination of substances from the mouth 
and lubrication of the oral mucosa reduced [13]. When the production of saliva decreases, 
the buffering capacity of the saliva is reduced, and thus the environment of the oral cavity 
is vulnerable to acidification, which in addition to determining changes in the normal flora 
(ecological imbalance) has contributed to the increase in the number of some microorganisms 
such as Candida albicans (a salivary flow less than 0.1 mL/min may cause an increase in the 
incidence of this fungus) and Streptococcus mutans (Gram-negative bacteria). A higher propor-
tion of these microorganisms results in greater acidification of the oral cavity environment, 
and thus contribute to the enamel demineralization and caries progression. There is a study 
related to it in which subjects with low salivary flow rate also had significantly more dental 
caries compared to those with a higher saliva flow rate [58]. In addition, high caries preva-
lence has been reported to be associated with significantly poorer quality of life compared to 
low caries prevalence [13].
The infection of the oral mucosa with C. albicans affects the lubrication of oral tissues, favoring 
an increase in the risk of caries and severity of periodontal disease. Candidiasis can also cause 
burning sensation, glossodynia, glossitis, and angular cheilitis (in areas where the lips are dry 
or cracked). Patients with prostheses may have reduced retention of the prostheses, pain, and 
ulcers [59]. The prevalence of oral Candida in the normal population has been estimated to 
range from 23 to 68% and 68 to 100% among SS patients. Studies have attributed the higher 
prevalence of oral Candida carriage in this disease to xerostomia [60].
6. Treatments
Treatment design to alleviate dry-mouth symptoms should be personalized to the individual 
patient, based on available treatment. The treatments of xerostomia can be classified into the 
following categories: (1) patient education, (2) prevention, (3) symptomatic treatment, (4) sys-
temic and topical salivary stimulants, and (5) regenerative and gene therapies.
6.1. Patient education
Patients should receive detailed information about the potential causes of dry mouth and the 
potential sequelae of impaired salivary secretion, such as dental caries, candidiasis, and muco-
sal complications. Therefore, patients should be encouraged to have preventive oral health 
care such as dental hygiene habits and regular dental visits [61]. Another palliative action 
to minimizing symptoms and preventing oral complications is water intake, drinking water 
frequently, and remaining hydrated is an important treatment for symptoms of dry mouth [1].
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6.2. Preventive therapies
Pharmacological interventions for the prevention of radiation-induced salivary gland dysfunc-
tion have been studied. The use of chemical radioprotectors represents an obvious strategy 
to improve the therapeutic index in radiotherapy. However, the vast majority of these are 
either too weak in terms of radioprotection, too toxic, or without any apparent mechanisms 
to ensure selective normal tissue protection [62]. The sulfhydryl compound amifostine (WR-
2721; 2-[(3-aminopropyl) amino] ethylphosphorothioic acid), is an oxygen scavenger that may 
protect salivary glands from free-radical damage during radiation therapy without attenuation 
of the anti-tumor effects in many experiments performed [63]. Amifostine has been approved 
for prevention of xerostomia, in head and neck squamous cell carcinoma patients undergoing 
radiotherapy [64]. A recent systematic review that included randomized controlled trials sug-
gested that the drug amifostine prevents the feeling of dry mouth in people receiving radio-
therapy to head and neck (with or without chemotherapy) in the short- (end of radiotherapy) to 
medium-term (3 months after radiotherapy) [65]. However, amifostine has adverse effects such 
as nausea, vomiting, hypotension, transient, hypocalcemia, and allergic reactions [66]. Then, 
the benefits of amifostine should be weighed against its high cost and side effects. Another cyto-
protective compound described in literature is the bioactive factor Keratinocyte growth factor-1 
(KGF-1, also known as FGF-7) [67]. In a phase II Study, recombinant KGF (Palifermin) appeared 
to reduce mucositis, dysphagia, and xerostomia during hyperfractionated radiotherapy but not 
standard radiation therapy [68].
Current preventative therapies also include surgical salivary glands relocation outside the 
radiation field [69]. Jha et al. described a surgical transfer of a submandibular salivary gland 
to the submental space in order to prevent radiation-induced xerostomia in patients with 
neoplasias of the pharynx and larynx [70].
6.3. Symptomatic treatment
Saliva substitutes can provide some relief since provide higher viscosity and protection to the 
oral mucosa [39]. An ideal saliva substitute must simulate natural human saliva, providing 
long lasting and intense hydration of the oral mucosa, be inexpensive, edible, easy-to-swallow 
but retainable in the mouth and should allow a minimal number of applications [71]. Saliva 
substitutes are available in various formulations, e.g., lozenges, sprays, mouth rinses, gels, oils, 
chewing gums, or toothpastes. Most available in the market contain carboxymethylcellulose 
(CMC), mucins, xanthan gum, hydroxyethylcellulose, linseed oil, or polyethylene oxide [72]. 
Subjective impressions of patients suffering from severe xerostomia showed that artificial saliva 
containing mucins and xanthan gum are better in their rheological and moisturizing proper-
ties than those with CMC [73], because mucin-based substitutes had viscosities that were more 
similar to natural saliva. Recently, it was reported that a polysaccharide-based oral rinse was 
effective in symptom control in patients with xerostomia and may lead to an increase in saliva 
production [74]. Other studies include the use of natural products, in this line, a recent double-
blinded, placebo-controlled clinical trial, evaluated the efficacy of topical lycopene-enriched 
virgin olive oil. It showed an improvement of oral quality of life and reduction of xerosto-
mia symptoms [75]. Also, gelatinous substitutes of saliva showed a significant reduction of the 
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dryness-related complaints in patients suffering from severe xerostomia [76]. A randomized, 
double-blind, crossover study in patients affected by medication-induced xerostomia showed 
that two commercial mouthwash plus gel (GUM® Hydral versus Biotène® Oralbalance) achieve 
a significant improvement in oral health and xerostomia-related quality of life [77]. Recently, 
a novel edible saliva substitute, oral moisturizing jelly (OMJ), showed a higher grade of sat-
isfaction than a commercially available saliva gel [78]. In addition to the persistent feeling of 
dry mouth, people who suffer from xerostomia are very susceptible to bacterial, fungal, and 
other transmittable mouth infections. It is important that products also include human saliva’s 
enzymes (lactoperoxidase, lysozyme, and lactoferrin). Other important feature is to obtain a 
continuous oral lubrication. In this context, advances in hydrogel technologies and develop-
ment of buccal mucoadhesive polymers, allows the continuous release of substances that main-
tain oral hydration and also offer dental-care benefits for its use in treatment of xerostomia [79]. 
Other strategy involves the use of modified prosthetic structure designed to retain saliva or 
substitutes in patients who usually wear a dental prosthesis [4, 80].
6.4. Systemic and topical salivary stimulants
Pilocarpine and cevimeline are two systemic US Food and Drug Administration-approved 
systemic sialogogues for treatment of dry mouth; both can increase secretions and diminish 
xerostomic complaints in patients, although they must have functional salivary gland cells. 
Pilocarpine is a cholinergic parasympathomimetic agent that stimulates muscarinic choliner-
gic receptors on the surfaces of exocrine glands [81] and has been indicated for the treatment 
of xerostomia [2, 82]. The usual oral dosage for pilocarpine is 5–10 mg three times per day. The 
initial recommended dose is 5 mg three times per day oral route (OR), which can be increased 
up to 30 mg/day depending on response and tolerance. The onset of action is 30 min, and the 
duration of action is approximately 2–3 h. Common side effects include gastrointestinal upset, 
sweating, tachycardia, bradycardia, increased pulmonary secretions, increased smooth muscle 
tone, and blurred vision. Contraindications include gall bladder disease, angle closure glau-
coma, and renal colic [39, 83]. Cevimeline is a salivary gland stimulant with a stronger affinity 
for M3 muscarinic receptors [84]. Since it has no effect on M2 receptors, it shows fewer adverse 
effects when compared to pilocarpine, and besides, it has a long lasting action. The recom-
mended dose is 30 mg three times a day OR, and the most common associated side effect is 
dyspepsia. Bethanecol is another drug whose action mechanism is on M3 receptors. It has been 
used to decrease unwanted effects caused by antidepressant and antipsychotic drugs [85]. The 
dose indicated is four times a day in doses from 10 to 50 mg OR. Adverse effects, despite being 
infrequent, include nausea and diarrhea. Other drugs that have been put forward include drug 
with mucolytic properties such us bromhexine improved salivary secretion in patients with SS 
[86, 87]. Nizatidine, an H2 receptor antagonist alone or in combination with cisapride, showed 
a significant increase in salivary secretions of dry mouth patients [88, 89]. In addition, other 
drugs, such as neostigmine, distigmine, yohimbine, nicotinic, and malic acid have also been 
attributed positive effects in the treatment of xerostomia [3]. Medicinal herbs, such as jabo-
randi, betel nut, Iceland Moss and Longo Vital, also can stimulate salivary secretion [4].
In the case of tissue autoimmune-related xerostomia, immunologic agents have been used. 
Interferon alpha (IFN-α), a protein with antiviral and immunomodulating traits, was an 
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effective treatment for xerostomia linked to SS, improved salivary output and decreased com-
plaints of xerostomia without causing significant adverse medical events [7, 90]. Rituximab 
(anti-CD20 monoclonal antibody) and infliximab (anti-tumoral necrosis factor—TNF—mono-
clonal antibody) improved subjective and objective symptoms related to primary SS [91].
Topical salivary stimulants includes sugar-free chewing gum and jellybeans, they can increase 
salivary secretion by mechanical stimulation and improve the sensation of dry mouth. These 
products usually contain fluoride, chlorhexidine, calcium phosphate, and xylitol releasers [92, 93], 
which inhibits the growth of cariogenic bacteria and reduces the incidence of caries [94]. Direct 
stimulation with electrostimulating device mounted on an intra-oral removable appliance has 
been used in patients with salivary dysfunction with good results and no significant side-effects 
[95, 96]. Moreover, non-invasive electrical stimulation systems such as transcutaneous electrical 
nerve stimulation (TENS) was highly effective in stimulating whole salivary flow in patients 
with xerostomia and hyposalivation caused by DM and postmenopausal condition [97, 98]. 
Acupuncture as a method of xerostomia treatment is also cited, a recent randomized and con-
trolled pilot trial of acupuncture showed that acupuncture has beneficial effects on SS symptoms 
[99]. Other pilot study showed a preliminary evidence that auricular acupressure therapy may 
be effective in reducing xerostomia intensity in maintenance hemodialysis patients [100].
6.5. Glandular regeneration and gene therapy
Stem cell replacement therapy may be a good option to treat radiation-induced hyposalivation. 
Stem cell therapy attempts the repair of damaged salivary glands at the cellular level. In this 
regard, bone marrow stem cells, adipose tissue-derived stromal cells, dental pulp cells have been 
tested as a form of treatment for hyposalivation after radiotherapy [39]. Interestingly, human 
salivary stem/progenitor cells (hSSPCs) (derived from parotid and submandibular glands) can 
be cultured using the salisphere technique and can be introduced to a damaged salivary gland 
tissue to replace dead or damaged cells. In this context, Pringle et al. showed the presence of 
SSPCs in cultured human salipheres [101]. These cells were capable of self-renewal and differ-
entiation, which when transplanted into irradiated recipients and restored glandular function. 
Considering that an ultimate goal is to develop fully functioning bioengineered organs to replace 
lost or damaged. It was recently reported that a population of SSPCs can be reliably isolated 
and expanded in sufficient number, suitable for use in a unique 3D hydrogel model of a human 
implantable salivary gland [102]. However, independent and collaborative work in stem cells 
research and tissue engineering is still necessary to have fully functional human salivary glands.
Gene therapy involves injecting a vector with genetic information into a tissue to result in 
some beneficial change. Originally, gene transfer was considered for use in treating congenital 
genetic disorders, but the basic principles have now been applied virtually to every organ, 
for acquired as well as inherited disorders. Regarding salivary glands, Baum et al., in phase 
I/II study, showed an increased saliva flow rate from the targeted parotid gland, as well as a 
reduction in symptoms related to the radiation-induced xerostomia in subjects treated with 
the transferring of cDNA for human aquaporin-1 (hAQP1) through an adenoviral (Ad5) vec-
tor (AdhAQP1) [103]. Additionally, others genes (Gli1, human keratinocyte growth factor, and 
Tousled like kinase 1B) have been targeted and have shown promise in preventing salivary 
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hypofunction in a preclinical mouse [104, 105]. On the other hand, the use of small-interfering 
RNA (siRNA)-based gene silencing has provided protection of salivary gland from radiation-
induced apoptosis at preclinical level [106].
7. Conclusion
Patients with xerostomia are often a challenge regarding diagnosis and treatment, because 
although xerostomia is not considered a disease, it has a potential devastating effect on the 
oral cavity. Since dentists are generally challenged with this problem, it is important to have an 
appropriate comprehension of diverse causes of xerostomia to develop a systematic approach 
that includes collaboration with physicians to facilitate interdisciplinary patient care, which 
involves its systemic conditions and medication. Furthermore, a comprehensive management 
of xerostomia is also necessary and it should incorporate patient education, lifestyle modifi-
cations, and adequate pharmacological and non-pharmacological therapies to improve the 
patient’s quality of life. Since most of the successful therapies are depending on the parenchy-
mal gland affection, it is essential to know new therapeutic approaches to fully recover in vivo 
the gland’s function or to develop new bioengineered salivary tissues.
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